Category

HTTP 200 OK
Allow: GET, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "count": 47,
    "next": "http://api.gregory-ms.com/categories/?format=api&page=2",
    "previous": null,
    "results": [
        {
            "category_id": 2,
            "category_description": "LEMTRADA, or Alemtuzumab, is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.\n\nhttps://www.lemtrada.com/",
            "category_name": "Alemtuzumab",
            "category_slug": "alemtuzumab",
            "category_terms": [
                "alemtuzumab",
                "lemtrada"
            ],
            "article_count": 114
        },
        {
            "category_id": 3,
            "category_description": "",
            "category_name": "Bexarotene",
            "category_slug": "bexarotene",
            "category_terms": [
                "bexarotene"
            ],
            "article_count": 3
        },
        {
            "category_id": 4,
            "category_description": "",
            "category_name": "Cladribine",
            "category_slug": "clabidrine",
            "category_terms": [
                "clabidrine",
                "mavenclad"
            ],
            "article_count": 1
        },
        {
            "category_id": 6,
            "category_description": "",
            "category_name": "Metformin",
            "category_slug": "metformin",
            "category_terms": [
                "metformin"
            ],
            "article_count": 21
        },
        {
            "category_id": 7,
            "category_description": "",
            "category_name": "Natalizumab",
            "category_slug": "natalizumab",
            "category_terms": [
                "natalizumab",
                "tysabri"
            ],
            "article_count": 298
        },
        {
            "category_id": 8,
            "category_description": "",
            "category_name": "Ocrelizumab",
            "category_slug": "ocrelizumab",
            "category_terms": [
                "ocrelizumab",
                "ocrevus"
            ],
            "article_count": 224
        },
        {
            "category_id": 9,
            "category_description": "",
            "category_name": "Simvastatin",
            "category_slug": "simvastatin",
            "category_terms": [
                "simvastatin"
            ],
            "article_count": 1
        },
        {
            "category_id": 10,
            "category_description": "",
            "category_name": "Tcelna",
            "category_slug": "tcelna",
            "category_terms": [
                "tcelna"
            ],
            "article_count": 0
        },
        {
            "category_id": 12,
            "category_description": "Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and other stem cell therapies",
            "category_name": "Stem Cells",
            "category_slug": "stem-cells",
            "category_terms": [
                "stem cells",
                "Autologous hematopoietic stem cell",
                "ahsct"
            ],
            "article_count": 225
        },
        {
            "category_id": 13,
            "category_description": "Siponimod (also known as BAF312 or Mayzent) is a tablet being developed for secondary progressive MS by Novartis Pharmaceuticals. It was licensed by the European Medicines Agency (EMA) on Monday 20 January 2020.\n\nhttps://www.mssociety.org.uk/research/explore-our-research/emerging-research-and-treatments/explore-treatments-in-trials/siponimod",
            "category_name": "Siponimod",
            "category_slug": "siponimod",
            "category_terms": [
                "siponimod",
                "BAF312",
                "Mayzent"
            ],
            "article_count": 45
        }
    ]
}